Core Viewpoint - The article highlights the recent developments of BGI Biotechnology (博安生物), including a significant shareholder transfer and the approval of its biosimilar drug BA6101 in Bolivia [1]. Group 1: Shareholder Activity - On January 13, BGI Biotechnology's shareholders transferred stocks from China Securities Registration and Clearing Hong Kong to CITIC Securities Brokerage Hong Kong, with a market value of HKD 512 million, accounting for 8.76% of the total shares [1]. Group 2: Product Approval - On January 13, BGI Biotechnology announced that its self-developed drug BA6101 (60mg) has been approved for market release by Bolivia's National Medicines and Health Technologies Agency (AGEMED) [1]. - BA6101 is a biosimilar referencing the original drug Prolia®, which is widely used globally for the treatment of osteoporosis [1].

1月13日，博安生物发布公告，其自主研发的地舒单抗注射液(60mg)(代号BA6101)已获玻利维亚国家药 品和卫生技术局(AGEMED)批准上市。BA6101为原研参照药Prolia的生物类似药，在全球范围内Prolia 广泛应用于骨质疏松症的治疗。 香港联交所最新资料显示，1月13日，博安生物(06955)股东将股票由中国证券登记结算香港转入中信证 券经纪香港，转仓市值5.12亿港元，占比8.76%。 ...

Core Viewpoint - The company has announced an increase in trading volume of its H-shares on January 9, 2026, and confirmed no knowledge of any reasons for this change, aside from disclosed information regarding the issuance of exchangeable preferred shares by its controlling shareholder, Luye Pharma Group [1][2] Group 1: Share Issuance and Trading - Luye Pharma Group's wholly-owned subsidiary, Luye Geneora Holding Limited, issued exchangeable preferred shares on December 12, 2025, which can be exchanged for 100.5 million H-shares held by Luye Pharma Group [1][2] - To comply with the agreement related to the exchangeable preferred shares, Luye Pharma Group arranged for its subsidiary, Shandong Luye Pharmaceutical Co., Ltd., to transfer 50 million H-shares to the issuer on the market [1] Group 2: Product Development and Approval - The company announced that its self-developed drug, BA6101 (60mg), has been approved for marketing by Bolivia's National Medicines and Health Technologies Authority (AGEMED) [2] - BA6101 is a biosimilar to the reference drug Prolia, widely used for the treatment of osteoporosis, and shares the same indications as the reference drug [2][3] - The development of BA6101 adhered to international guidelines, confirming its overall similarity to the reference drug in terms of quality, safety, and efficacy [3] Group 3: Commercialization Strategy - The company plans to commercialize BA6101 in Bolivia and has established strategic partnerships for its commercialization in other Latin American markets, the United States, Southeast Asia, Hong Kong, and Macau [3] - The company aims to accelerate its international strategy by providing high-quality domestic biopharmaceuticals, including BA6101, to meet global patient treatment needs [3]